Clinical Trial Update: The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ferric derisomaltose for improving exercise capacity and quality of life in patients with acute heart failure and iron deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction
• Iron Deficiency

Drugs mentioned

• Ferric derisomaltose (ferric derisomaltose)

Snippet

Sponsor: China-Japan Friendship Hospital | Conditions: Heart Failure With Preserved Ejection Fraction, Iron Deficiencies | Phase 4 | Status: UNKNOWN